MARQUEE_2B: MARQUEE, figure 2B

MARQUEE_2BR Documentation

MARQUEE, figure 2B

Description

Kaplan-Meier digitized data from MARQUEE, figure 2B (PMID 26169611). A reported sample size of 1,048 for a primary endpoint of OS in lung cancer.

Usage

MARQUEE_2B

Format

A data frame of 1,048 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (erlotinib_placebo, erlotinib_tivantinib)

Source

Scagliotti G, von Pawel J, Novello S, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2667–74.

Examples

summary(MARQUEE_2B)

kmplot(MARQUEE_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.